Meet Our Leadership
Sushil K. Mahata, Ph.D.
Dr. Sushil K. Mahata is a Professor of Medicine at the University of California San Diego (UC San Diego), a Research Physiologist at the VA San Diego Healthcare System, a Research Scientist at the Veterans Medical Research Foundation, and Founder and President of CgA Therapeuticals, Inc.
Read MoreManjula Mahata, Ph.D.
Dr. Manjula Mahata is the Chief Scientific Officer (CSO) of CgA Therapeuticals, Inc., where she leads the company's scientific and translational research programs focused on developing catestatin (CST)-based peptide and peptidomimetic therapeutics. She received her Ph.D. in Comparative Endocrinology from the University of Calcutta, India, in 1991, followed by advanced research training in Europe and the United States. Her research has focused extensively on chromogranin A (CgA), catestatin, and their roles in health and disease.
Read MoreCristina Rodriguez Rios, Attorney
Ms. Rodriguez Rios has over fifteen years of experience in the areas of corporate law, finance, and international transactions. She has a broad-based corporate practice, which includes the provision of general counsel services for clients, international transactions, corporate formation and governance, mergers and acquisitions, real estate financing and commercial leasing, venture capital financing, antitrust compliance, telecommunications law and intellectual property licensing.
Read MoreAbout the drug
Catestatin is a novel endogenous peptide that regulates cardiac function and blood pressure. Catestatin (CST) is a peptide derived by proteolytic digestion from the pro-protein Chromogranin A, a secretagogue expressed in neuroendocrine tissues and macrophages. It prevents catecholamine production by inhibiting neural acetylcholine receptor activity. As a result, CST can reduce essential hypertension.
Read MoreAbout the patent
The invention provides methods for treating obesity in a subject comprising administrating an effective amount of CST or its equivalent to a subject afflicted with obesity so as to maintain an effective amount of circulating CST in the subject to promote lipolysis and oxidation of released fatty acids in both liver and adipose tissue, thereby, reducing adipose tissue weight and hence treating obesity in the afflicted subject.
Read MoreAbout the application
CST will be an injectable solution in physiological saline and each injection will deliver 1 microgram CST per gm body weight. In other words, it will be 90 mg CST for a person weighing 90 kg or 200 lb. It may be injected twice daily to get more effective control of the diseases. Injection site could be subcutaneous like insulin injection.
Read MoreInformation about grant
Granting Period 10/01/2017 to 9/30/2021
VA Merit Review grant on “Catestatin improves glucose homeostatsis and insulin sensitivity in diet induced obese mice”. Total funding amount is $ 1,901,105.70